Evidence map›Paper›PMID 38074312›Full record

ArticleFuture virology2023

Resistance analysis following sotrovimab treatment in participants with COVID-19 during the phase III COMET-ICE study.

Sambhavi Subramanian, Gretja Schnell, Julia di Iulio, Anil K Gupta, Adrienne E Shapiro, Elias H Sarkis, Amanda Lopuski, Amanda Peppercorn, Melissa Aldinger, Christy M Hebner and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Future virology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Sambhavi SubramanianVir Biotechnology, Inc., San Francisco, CA, USA.
Gretja SchnellVir Biotechnology, Inc., San Francisco, CA, USA.
Julia di IulioVir Biotechnology, Inc., San Francisco, CA, USA.ORCID https://orcid.org/0000-0001-9343-127X
Anil K GuptaWilliam Osler Health Centre, Etobicoke, Ontario, Canada.
Adrienne E ShapiroUniversity of Washington & Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID https://orcid.org/0000-0002-3106-1258
Elias H SarkisSarkis Clinical Trials, Gainesville, FL, USA.ORCID https://orcid.org/0000-0002-5477-8059
Amanda LopuskiGSK, Cambridge, MA, USA.
Amanda PeppercornGSK, Cambridge, MA, USA.
Melissa AldingerVir Biotechnology, Inc., San Francisco, CA, USA.
Christy M HebnerVir Biotechnology, Inc., San Francisco, CA, USA.
Andrea L CathcartVir Biotechnology, Inc., San Francisco, CA, USA.ORCID https://orcid.org/0000-0002-3928-8828
VIR Biotechnology (United States) · USUniversity of Washington · USWilliam Osler Health System · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

antiviral resistanceCOVID-19monoclonal antibodySARS-CoV-2sotrovimab

Identifiers

PMID38074312
PMCPMC10705769
OpenAlexW4389802458

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.